Ildong Holdings Co., Ltd. (000230.KS)
KRW 6600.0
(-5.44%)
KRW 6600.0
(-5.44%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 310.87 Billion KRW | 41.87% |
| 2022 | 219.12 Billion KRW | 46.62% |
| 2021 | 149.45 Billion KRW | 25.99% |
| 2020 | 118.61 Billion KRW | -9.33% |
| 2019 | 130.81 Billion KRW | 287.94% |
| 2018 | 33.72 Billion KRW | 6.8% |
| 2017 | 31.57 Billion KRW | 260.75% |
| 2016 | 8.75 Billion KRW | -92.79% |
| 2015 | 121.44 Billion KRW | -8.35% |
| 2014 | 132.51 Billion KRW | 7.95% |
| 2013 | 122.75 Billion KRW | 60.11% |
| 2012 | 76.67 Billion KRW | 43.07% |
| 2011 | 53.58 Billion KRW | -47.75% |
| 2010 | 102.55 Billion KRW | 12.7% |
| 2009 | 90.99 Billion KRW | -0.15% |
| 2008 | 91.13 Billion KRW | 86.23% |
| 2007 | 48.93 Billion KRW | 100.72% |
| 2006 | 24.38 Billion KRW | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 323.46 Billion KRW | 4.05% |
| 2024 Q2 | 314.99 Billion KRW | -2.62% |
| 2023 Q4 | 310.87 Billion KRW | 3.78% |
| 2023 Q1 | 236.88 Billion KRW | 8.1% |
| 2023 Q2 | 296.62 Billion KRW | 25.22% |
| 2023 FY | 310.87 Billion KRW | 41.87% |
| 2023 Q3 | 299.55 Billion KRW | 0.99% |
| 2022 Q3 | 202.19 Billion KRW | 8.64% |
| 2022 Q1 | 152.97 Billion KRW | 2.36% |
| 2022 FY | 219.12 Billion KRW | 46.62% |
| 2022 Q4 | 219.12 Billion KRW | 8.37% |
| 2022 Q2 | 186.11 Billion KRW | 21.66% |
| 2021 Q1 | 122.51 Billion KRW | 3.28% |
| 2021 FY | 149.45 Billion KRW | 25.99% |
| 2021 Q4 | 149.45 Billion KRW | 21.45% |
| 2021 Q3 | 123.05 Billion KRW | 4.97% |
| 2021 Q2 | 117.23 Billion KRW | -4.31% |
| 2020 Q2 | 153.45 Billion KRW | 7.74% |
| 2020 Q1 | 142.42 Billion KRW | 8.87% |
| 2020 FY | 118.61 Billion KRW | -9.33% |
| 2020 Q3 | 155.38 Billion KRW | 1.26% |
| 2020 Q4 | 118.61 Billion KRW | -23.66% |
| 2019 FY | 130.81 Billion KRW | 287.94% |
| 2019 Q4 | 130.81 Billion KRW | -1.84% |
| 2019 Q2 | 36.8 Billion KRW | -5.59% |
| 2019 Q1 | 38.98 Billion KRW | 15.6% |
| 2019 Q3 | 133.26 Billion KRW | 262.09% |
| 2018 Q2 | 32.58 Billion KRW | 5.25% |
| 2018 Q1 | 30.96 Billion KRW | -1.93% |
| 2018 FY | 33.72 Billion KRW | 6.8% |
| 2018 Q4 | 33.72 Billion KRW | -4.48% |
| 2018 Q3 | 35.3 Billion KRW | 8.33% |
| 2017 Q4 | 31.57 Billion KRW | 19.59% |
| 2017 FY | 31.57 Billion KRW | 260.75% |
| 2017 Q1 | 9.58 Billion KRW | 9.55% |
| 2017 Q2 | -38.38 Billion KRW | -500.3% |
| 2017 Q3 | 26.4 Billion KRW | 168.79% |
| 2016 Q1 | 110.28 Billion KRW | -9.19% |
| 2016 Q4 | 8.75 Billion KRW | 97.94% |
| 2016 Q3 | 4.42 Billion KRW | 106.6% |
| 2016 Q2 | -67.02 Billion KRW | -160.77% |
| 2016 FY | 8.75 Billion KRW | -92.79% |
| 2015 Q4 | 121.44 Billion KRW | -8.05% |
| 2015 FY | 121.44 Billion KRW | -8.35% |
| 2015 Q3 | 132.06 Billion KRW | 1.55% |
| 2015 Q2 | 130.05 Billion KRW | -0.74% |
| 2015 Q1 | 131.02 Billion KRW | -1.13% |
| 2014 FY | 132.51 Billion KRW | 7.95% |
| 2014 Q4 | 132.51 Billion KRW | -5.99% |
| 2014 Q3 | 140.95 Billion KRW | 1.08% |
| 2014 Q2 | 139.44 Billion KRW | 1.81% |
| 2014 Q1 | 136.97 Billion KRW | 11.58% |
| 2013 Q4 | 122.75 Billion KRW | 1.93% |
| 2013 FY | 122.75 Billion KRW | 60.11% |
| 2013 Q3 | 120.42 Billion KRW | 6.14% |
| 2013 Q1 | 97.07 Billion KRW | 26.61% |
| 2013 Q2 | 113.46 Billion KRW | 16.89% |
| 2012 FY | 76.67 Billion KRW | 43.07% |
| 2012 Q4 | 76.67 Billion KRW | 0.0% |
| 2012 Q1 | 63.99 Billion KRW | 0.0% |
| 2011 Q1 | 62.62 Billion KRW | 0.0% |
| 2011 Q2 | 53.75 Billion KRW | -14.17% |
| 2011 Q3 | 51.33 Billion KRW | -4.5% |
| 2011 FY | 53.58 Billion KRW | -47.75% |
| 2010 Q2 | 66.15 Billion KRW | 0.0% |
| 2010 Q3 | 71.17 Billion KRW | 7.59% |
| 2010 FY | 102.55 Billion KRW | 12.7% |
| 2009 Q4 | 78.9 Billion KRW | 0.1% |
| 2009 Q3 | 78.82 Billion KRW | 20.41% |
| 2009 FY | 90.99 Billion KRW | -0.15% |
| 2009 Q2 | 65.46 Billion KRW | 0.0% |
| 2008 Q4 | 38.72 Billion KRW | -2.15% |
| 2008 Q2 | 29.44 Billion KRW | 0.0% |
| 2008 Q3 | 39.57 Billion KRW | 34.4% |
| 2008 FY | 91.13 Billion KRW | 86.23% |
| 2007 FY | 48.93 Billion KRW | 100.72% |
| 2007 Q2 | 26.45 Billion KRW | 0.0% |
| 2007 Q4 | 31.91 Billion KRW | 11.95% |
| 2007 Q3 | 28.5 Billion KRW | 7.77% |
| 2006 FY | 24.38 Billion KRW | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 8.8 Billion KRW | -3431.735% |
| Dong-A Socio Holdings Co., Ltd. | 572.02 Billion KRW | 45.654% |
| HANDOK Inc. | 283.45 Billion KRW | -9.672% |
| Kukje Pharma Co., Ltd. | 20.07 Billion KRW | -1448.772% |
| Yuhan Corporation | -69.18 Billion KRW | 549.325% |
| Dong-A ST Co., Ltd. | 193.95 Billion KRW | -60.284% |
| SAMSUNG PHARM. Co., LTD. | -3.68 Billion KRW | 8534.288% |
| Hanmi Pharm. Co., Ltd. | 517.88 Billion KRW | 39.973% |
| Hanall Biopharma Co.,Ltd | -32.43 Billion KRW | 1058.538% |
| Ilyang Pharmaceutical Co.,Ltd | 75.67 Billion KRW | -310.801% |
| Dong Sung Bio Pharm.Co.,Ltd. | 36.83 Billion KRW | -743.905% |
| MYUNGMOON Pharm co.,Ltd | 82.52 Billion KRW | -276.722% |
| Hana Pharm Co., Ltd. | 25.1 Billion KRW | -1138.12% |
| Yuyu Pharma, Inc. | 8.8 Billion KRW | -3431.735% |
| Ilsung Pharmaceuticals Co., Ltd. | -159.84 Billion KRW | 294.481% |
| REYON Pharmaceutical Co., Ltd. | 200.94 Billion KRW | -54.704% |
| Aprogen pharmaceuticals,Inc. | 170.94 Billion KRW | -81.857% |
| JW Holdings Corporation | 480.68 Billion KRW | 35.328% |
| Ildong Pharmaceutical Co., Ltd. | 164.58 Billion KRW | -88.885% |
| Chong Kun Dang Pharmaceutical Corp. | 117.53 Million KRW | -264401.325% |
| JW Pharmaceutical Corporation | 154.37 Billion KRW | -101.38% |
| Shin Poong Pharm.Co.,Ltd. | 2.35 Billion KRW | -13121.186% |
| Hyundai Pharmaceutical Co., Ltd. | 23 Billion KRW | -1251.534% |
| Samil Pharmaceutical Co.,Ltd | 174.97 Billion KRW | -77.669% |
| Jeil Pharmaceutical Co.,Ltd | 51.97 Billion KRW | -498.123% |
| Yuyu Pharma, Inc. | 8.8 Billion KRW | -3431.735% |
| Kwang Dong Pharmaceutical Co., Ltd. | 158.29 Billion KRW | -96.386% |
| Daewoong pharmaceutical Co.,Ltd | 358.17 Billion KRW | 13.207% |
| JW Pharmaceutical Corporation | 154.37 Billion KRW | -101.38% |
| Yuhan Corporation | -69.18 Billion KRW | 549.325% |
| Jeil Pharma Holdings Inc | 135.99 Billion KRW | -128.597% |
| Yungjin Pharm. Co., Ltd. | 59.67 Billion KRW | -420.949% |
| Suheung Co., Ltd. | 429.14 Billion KRW | 27.561% |
| JW Pharmaceutical Corporation | 154.37 Billion KRW | -101.38% |
| Samjin Pharmaceuticals Co., Ltd. | 116.23 Billion KRW | -167.448% |
| Korea United Pharm Inc. | 16.42 Billion KRW | -1792.665% |
| CKD Bio Corp. | 143.29 Billion KRW | -116.944% |
| Daewon Pharmaceutical Co., Ltd. | 116.06 Billion KRW | -167.838% |
| Dongwha Pharm.Co.,Ltd | -24.06 Billion KRW | 1391.979% |
| Whan In Pharm Co.,Ltd. | -44.73 Billion KRW | 794.934% |
| Shin Poong Pharm.Co.,Ltd. | 2.35 Billion KRW | -13121.186% |
| Chong Kun Dang Holdings Corp. | 422.84 Billion KRW | 26.48% |
| Boryung Corporation | 187.72 Billion KRW | -65.597% |
| Bukwang Pharmaceutical Co., Ltd. | -71.84 Billion KRW | 532.728% |
| Ilyang Pharmaceutical Co.,Ltd | 75.67 Billion KRW | -310.801% |
| JW Lifescience Corporation | 26.09 Billion KRW | -1091.506% |